|
WO1997036861A1
(en)
*
|
1996-03-29 |
1997-10-09 |
G.D. Searle & Co. |
Meta-substituted phenylene sulphonamide derivatives
|
|
GB9805655D0
(en)
|
1998-03-16 |
1998-05-13 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6521626B1
(en)
|
1998-03-24 |
2003-02-18 |
Celltech R&D Limited |
Thiocarboxamide derivatives
|
|
CN1140511C
(zh)
|
1998-04-09 |
2004-03-03 |
明治制果株式会社 |
作为整合素αvβ3拮抗剂的氨基哌啶衍生物
|
|
GB9814414D0
(en)
|
1998-07-03 |
1998-09-02 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
WO2000006169A1
(en)
*
|
1998-07-29 |
2000-02-10 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
IL143870A0
(en)
|
1998-12-23 |
2002-04-21 |
Searle & Co |
Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6291503B1
(en)
|
1999-01-15 |
2001-09-18 |
Bayer Aktiengesellschaft |
β-phenylalanine derivatives as integrin antagonists
|
|
US6518283B1
(en)
|
1999-05-28 |
2003-02-11 |
Celltech R&D Limited |
Squaric acid derivatives
|
|
EP1209152A4
(en)
|
1999-08-05 |
2003-03-12 |
Meiji Seika Kaisha |
OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
|
|
WO2001017953A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Guilford Pharmaceuticals Inc. |
Non-peptidic cyclophilin binding compounds and their use
|
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
|
US6534513B1
(en)
|
1999-09-29 |
2003-03-18 |
Celltech R&D Limited |
Phenylalkanoic acid derivatives
|
|
US20050059669A1
(en)
*
|
1999-10-08 |
2005-03-17 |
Keiichi Ajito |
M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
|
|
EP1227083A4
(en)
*
|
1999-10-08 |
2002-11-20 |
Meiji Seika Kaisha |
3-AMINOPIPERIDE DERIVATIVES AS INTEGRIN- $ g (a) v $ g (b) 3-ANTAGONISTS
|
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
|
US6455539B2
(en)
|
1999-12-23 |
2002-09-24 |
Celltech R&D Limited |
Squaric acid derivates
|
|
WO2001056607A1
(en)
*
|
2000-02-03 |
2001-08-09 |
Eisai Co., Ltd. |
Integrin expression inhibitors
|
|
ATE375330T1
(de)
|
2000-04-17 |
2007-10-15 |
Ucb Pharma Sa |
Enamin-derivate als zell-adhäsionsmoleküle
|
|
US6545013B2
(en)
|
2000-05-30 |
2003-04-08 |
Celltech R&D Limited |
2,7-naphthyridine derivatives
|
|
US6403608B1
(en)
|
2000-05-30 |
2002-06-11 |
Celltech R&D, Ltd. |
3-Substituted isoquinolin-1-yl derivatives
|
|
WO2002004426A1
(en)
|
2000-07-07 |
2002-01-17 |
Celltech R & D Limited |
Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
|
|
AU2001275724A1
(en)
|
2000-08-02 |
2002-02-13 |
Celltech R&D Limited |
3-substituted isoquinolin-1-yl derivatives
|
|
JP2004532187A
(ja)
|
2001-01-25 |
2004-10-21 |
ギルフォード ファーマシュウティカルズ インコーポレイテッド |
三置換カルボサイクリックサイクロフィリン結合化合物とその用途
|
|
CN100384482C
(zh)
*
|
2001-02-21 |
2008-04-30 |
卫材R&D管理有限公司 |
测定通过抑制整联蛋白表达所介导的血管生成抑制剂的作用的方法
|
|
US6710061B2
(en)
*
|
2001-03-09 |
2004-03-23 |
Ortho-Mcneil Pharamceutical, Inc. |
Aminopyrrolidine sulfonamides as serine protease inhibitors
|
|
GB0127615D0
(en)
*
|
2001-07-09 |
2002-01-09 |
Aventis Pharm Prod Inc |
Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
|
|
JP4750360B2
(ja)
|
2001-10-22 |
2011-08-17 |
ザ スクリプス リサーチ インスティチュート |
抗体ターゲッティング化合物
|
|
AU2002364260A1
(en)
*
|
2001-12-31 |
2003-07-30 |
Bayer Pharmaceuticals Corporation |
Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
|
|
JP2005533001A
(ja)
*
|
2002-03-04 |
2005-11-04 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
|
|
CA2478317A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
|
|
AU2004207002A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US9296697B2
(en)
|
2005-08-24 |
2016-03-29 |
Abbott Laboratories |
Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
|
|
WO2007048127A2
(en)
*
|
2005-10-20 |
2007-04-26 |
The Scripps Research Institute |
Fc labeling for immunostaining and immunotargeting
|
|
EP2222636B1
(en)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
JP2012517447A
(ja)
|
2009-02-10 |
2012-08-02 |
ザ スクリプス リサーチ インスティチュート |
化学的にプログラムされたワクチン接種法
|
|
RU2016146826A
(ru)
|
2014-05-30 |
2018-07-04 |
Пфайзер Инк. |
Производные карбонитрилов как селективные модуляторы андрогенового рецептора
|
|
KR20220003554A
(ko)
|
2019-04-19 |
2022-01-10 |
리간드 파마슈티칼스 인코포레이티드 |
화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
|
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|